Astellas Pharma Inc (ALPMY)

Currency in USD
10.13
+0.44(+4.49%)
Delayed Data·

ALPMY Financial Summary

Key Ratios

P/E Ratio52.39
Price/Book1.63
Debt / Equity61.93%
Return on Equity3.26%
Dividend Yield0.00%
EBITDA462.67B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/03
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of JPY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 28.35%
Dividend Yield
-
Industry Median 2.84%
Annualised payout
-
Paid unevenly
5-Years Growth
-
Growth Streak

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 11.30
(+11.55% Upside)

Earnings

Latest Release
Apr 25, 2025
EPS / Forecast
0.2929 / 0.1349
Revenue / Forecast
3.22B / 2.74B
EPS Revisions
Last 90 days

FAQ

What were Astellas Pharma Inc's earnings for the latest quarter?

The Astellas Pharma Inc EPS (TTM) is 28.35. Astellas Pharma Inc reported sales of 459,294.00, net income of 74,896.00, and EPS of 0.29 for the latest quarter.

What was Astellas Pharma Inc's net income for the latest quarter?

Astellas Pharma Inc's net income for the latest quarter was 74,896.00.

How did Astellas Pharma Inc's performance compare year-over-year in the latest quarter?

The company's revenue moved from 517,408.00 in the previous quarter to 459,294.00 in the latest quarter, and net income moved from -97,660.00 to 74,896.00 compared to the previous quarter.

What is Astellas Pharma Inc's net profit margin on a TTM basis?

Astellas Pharma Inc's trailing twelve months (TTM) net profit margin is 2.65%.

How does Astellas Pharma Inc's debt to equity ratio compare to industry standards?

Astellas Pharma Inc's total debt-to-equity ratio is 61.93%.

What is Astellas Pharma Inc's return on investment on a TTM basis?

Astellas Pharma Inc's trailing twelve months (TTM) return on investment (ROI) is 3.26%.

Did Astellas Pharma Inc gain or lose cash last quarter?

In the latest quarter, Astellas Pharma Inc's net change in cash was 8,506.00 million.

What were Astellas Pharma Inc's total assets and liabilities in the latest quarter?

As of the latest quarter, Astellas Pharma Inc reported total assets of 3,339,544.00 million and total liabilities of 1,061,610.00 million.

How has Astellas Pharma Inc's total revenue grown this year?

Astellas Pharma Inc's total revenue was 517,408.00 in the previous quarter and 459,294.00 in the latest quarter.

What is Astellas Pharma Inc's gross margin on a TTM basis?

Astellas Pharma Inc's trailing twelve months (TTM) gross margin is 81.74%.

What was Astellas Pharma Inc's revenue per share for the latest quarter?

Astellas Pharma Inc's revenue per share for the latest quarter was 43.97.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.